About
About RaQualia Pharma Inc
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. The company human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. It also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; RQ-00317076 for pain; and RQ-00000010 for gut motility disorders, gastroparesis, functional dyspepsia, and chronic constipation. In addition, it provides RQ-00433412 for constipation, and cancer-related anorexia/cachexia syndrome; RQ-00000009 to treat alzheimer's; RQ-00466479, RQ-00350215, and RQ-00434739 to treat chronic pain; RQ-00310941 to treat D-IBS, IBD-remission stage symptoms; RQ-00201894 for gastroparesis, functional dyspepsia, and post-operative ileus; tamibarotene to treat higher-risk myelodysplastic syndrome and acute myeloid leukemia; and FIM-001 for cancer. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
Visit company website
5 years, 6 months ago
RaQualia Pharma Inc is currently in a long term downtrend where the price is trading 4.6% below its 200 day moving average.
From a valuation standpoint, the stock is 72.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.7.
RaQualia Pharma Inc's total revenue sank by 46.3% to $534M since the same quarter in the previous year.
Its net income has dropped by 82.9% to $92M since the same quarter in the previous year.
Finally, its free cash flow fell by 6032.0% to $-260M since the same quarter in the previous year.
Based on the above factors, RaQualia Pharma Inc gets an overall score of 1/5.